Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2016

01-03-2016 | Research Article

Overexpression of CIP2A promotes bladder cancer progression by regulating EMT

Authors: X. Pang, X. Fu, S. Chen, X. Zhu, H. Qi, Y. Li, F. Li, W. Tan

Published in: Clinical and Translational Oncology | Issue 3/2016

Login to get access

Abstract

Background

Bladder cancer is the second most common urological malignancy worldwide. CIP2A is a newly identified inhibitor of PP2A. Recent studies have highlighted a potential role for CIP2A in promoting the proliferation of several cancer cells. However, the role of CIP2A in bladder cancer still remains unclear.

Methods

The expression of CIP2A was detected by quantitative real-time polymerase chain reaction and IHC in bladder cancer tissues and bladder cancer cell lines. In addition, silencing of CIP2A with siRNA was performed in T24 cells, and the impact on proliferation, and apoptosis of T24 cells was analyzed.

Results

Our results found that CIP2A expression levels were higher in bladder cancer tissues and cell lines. Furthermore, CIP2A siRNA significantly reduced the proliferation rate of T24 cells, induced a significant population of early and late apoptosis, and could reverse EMT in T24 cells, indicates that CIP2A expression is increased in bladder cancer and implies a role of the protein in bladder cancer progression.

Conclusions

These results suggest that CIP2A is involved in tumor progression, and thus CIP2A could represent selective targets for the targeted treatments of bladder cancer.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
2.
Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. Cancer Sci. 2008;99(4):646–52.CrossRefPubMed
3.
Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6):4–34.CrossRefPubMed
4.
Nargund VH, Tanabalan CK, Kabir MN. Management of non-muscle-invasive (superficial) bladder cancer. Semin Oncol. 2012;39(5):559–72.CrossRefPubMed
5.
Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006;66(23):11271–8.CrossRefPubMed
6.
Shan Y, Zhang L, Bao Y, Li B, He C, Gao M, et al. Epithelial–mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem. 2013;24(6):1062–9.CrossRefPubMed
7.
Yu Q, Zhang K, Wang X, Liu X, Zhang Z. Expression of transcription factors snail, slug, and twist in human bladder carcinoma. J Exp Clin Cancer Res. 2010;29:119.PubMedCentralCrossRefPubMed
8.
Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130(1):51–62.CrossRefPubMed
9.
Huang LP, Savoly D, Sidi AA, Adelson ME, Mordechai E, Trama JP. CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med. 2012;1(1):76–81.PubMedCentralCrossRefPubMed
10.
Wang L, Gu F, Ma N, Zhang L, Bian JM, Cao HY. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol. 2013;34(4):2309–13.CrossRefPubMed
11.
Kwak C, Lee SE, Jeong IG, Ku JH. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology. 2006;68(1):53–7.CrossRefPubMed
12.
Mhawech-Fauceglia P, Cheney RT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer. 2006;106(6):1205–16.CrossRefPubMed
13.
Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 2002;3:155–66.CrossRefPubMed
14.
15.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRefPubMed
16.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.CrossRefPubMed
Metadata
Title
Overexpression of CIP2A promotes bladder cancer progression by regulating EMT
Authors
X. Pang
X. Fu
S. Chen
X. Zhu
H. Qi
Y. Li
F. Li
W. Tan
Publication date
01-03-2016
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1366-z

Other articles of this Issue 3/2016

Clinical and Translational Oncology 3/2016 Go to the issue

Review Article

Central nervous system niche involvement in the leukemia

Research Article

Decreased expression of MicroRNA-200 family in human breast cancer is associated with lymph node metastasis

Research Article

XIAP inhibitor Embelin inhibits bladder cancer survival and invasion in vitro

Research Article

Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients

Review Article

The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer

Research Article

The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits